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I would like to take this opportunity to express my deepest gratitude to everyone who responded to my study entitled: “Trouble Spots in Online Direct-to-Consumer Prescription 
Drug Promotion: A Content Analysis of FDA Warning 
Letters.”1 Scholars from several different fields, including 
medical science, pharmacy, business, and communication 
have all participated in the discussion of current issues 
and the future of direct-to-consumer advertising (DTCA), 
bringing multifaceted viewpoints to bear on prescription 
drug marketing based on their own disciplines. It was a 
high honor and a truly gratifying experience to receive such 
valuable comments from colleagues in my own field, as well 
as scholars who have dedicated their research in DTCA of 
prescription drugs in other fields. I appreciate their insights 
into the research on online DTCA of prescription drugs, 
which enabled me to broaden my perspective on an area of 
prescription drug promotions that could not only influence 
consumers, but also other stakeholders, such as policy-
makers, clinicians, and marketers. These commentaries 
expand on ideas of current regulatory issues regarding online 
promotions, and discuss further unforeseen concerns that 
might arise due to emerging media options consumers will 
have in the future—all of which warrant more research and 
close scholarly attention. 
With the advent of new technologies and the variety of 
communication platforms available online, pharmaceutical 
marketers’ promotional tactics for prescription drugs have 
posed a lot of questions.1 DTCA is only permitted in the United 
States and New Zealand; however, Tim Mackey, Barbara 
Mintzes, Brian Southwell, and Douglas Rupert suggest further 
regulatory inquiries regarding the global reach of prescription 
drug DTCA,2-4 as the Internet has made it possible to reach 
people all around the world. Pharmaceutical manufacturers’ 
social media accounts and brand-specific websites are 
accessible to US and non-US consumers alike; although these 
online promotional venues indicate that they are intended only 
for US residents, pharmaceutical manufacturers rarely block 
non-US access.3,5 Virtually all English-speaking countries 
and English-speaking individuals can access prescription 
drug information from non-US markets. Canadian policy-
makers haves already been struggling with DTC broadcasting 
ads transmitted from the United States, and Health Canada 
maintains a watchdog function to block eDTCA content.2,6 
Online promotional content of prescription drugs can 
clearly cross international borders and has the potential to 
run faster and much farther away as technology advances. 
As such, eDTCA originating in the United States can result 
in unbidden consequences to consumers, policy-makers, 
and pharmaceutical practitioners outside the borders of the 
United States, where DTCA is not legal, as Mackey, Mintzes, 
Southwell and Rupert pointed out quite well. 
Based on key findings from my study, all the commentaries 
argue that off-labeling is the most serious problem resulting 
from eDTCA of prescription drugs, followed by the lack of 
substantial information associated with drug use. In addition, 
Southwell and Rupert suggest that such an issue becomes 
more serious on the mobile environment because mobile 
space is much more limited than that of the computer, and 
many online websites are still not mobile-friendly in their 
design, which raises questions as to how such broken and 
incomplete drug information available on mobile websites 
influences viewers.4 Also, a surprising finding from my study 
was that only 2 alleged violations were reported with regard to 
social media within the recent 10 year span, given the growing 
use and popularity of social media as a health information-
seeking channel.4,7 Issac Wanasika, therefore, strongly 
argues that drug manufacturers’ promotional activities on 
social media warrant closer scrutiny by the Food and Drug 
Administration (FDA).7 
Francesca Renee Dillman Carpentier specifically examined 
promotional activities of prescription drugs on social media, 
suggesting that, in many cases, social media content coupled 
with message source factor blurs the line between market-
controlled vs. market-influenced promotions.8 The nature 
of social media allows people to create messages, as well as 
simply share their own content or posts that someone else 
has already created. As such, it is often difficult to identify 
the source of the content; also, shared content, in the form 
of “retweeting” or “liking,” obscures where the content 
originated, which challenges whether the company or the 
consumers are responsible for the content.8 According to 
Southwell and Rupert, consumers are actively discussing their 
own experiences with prescription drugs with other fellow 
consumers—ie, patients or caregivers—on social media.4 They 
actively engage in conversations and share information with 
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like-minded people who have similar experiences. Dillman 
Carpentier also suggests, however, that there is no way to 
oversee branded user-generated content distributed outside 
of pharmaceutical companies’ control, which can affect 
public health.8 Thus, social media is much more complex and 
different from other types of online platforms, and therefore, 
requires close attention by policy-makers.
Another area that plays a significant role in eDTCA is 
help-seeking ads.3,9 Barbara Minzes argues that the help-
seeking type of ads—also referred to as disease-specific or 
disease awareness ads—can be problematic in the online 
environment because a “clicking” of the ads takes users to 
branded websites landing pages, which brings us back the 
“fair balance” dilemma.3 Based on a series of studies exploring 
disease-specific ads, Brent Rollins suggests, in terms of the 
disease prevention viewpoint, that disease-specific ads can be 
effective, as they encourage patients to discuss their symptoms 
with doctors and to seek health information.9 Disease-specific 
ads can be useful, but it is noteworthy that these ads are not 
free from the “fair balance” issue in online promotions. 
Drawing on the original study, these commentaries expanded 
the issues regarding DTCA and shed light on possible 
violations that do need careful scrutiny by policy-makers, 
including the FDA. The FDA’s warning letters have been 
studied by many scholars10,11; however, these letters may not 
be a sufficient data source for determining all the trouble 
spots concerning DTCA.2,3,7 Future research, thus, needs to 
look at DTCA from multiple angles, which indicates that 
an interdisciplinary approach would help in understanding 
the issues surrounding DTCA. I appreciate commenters 
who brought their expertise from their own fields in this 
regard. We study DTCA not merely to ban the ads or to 
force the FDA to issue more aggressive warning letters to 
pharmaceutical companies, but to provide trustful and helpful 
health information to consumers so they can make informed 
decisions. Admittedly, without comprehensive guidelines, 
pharmaceutical makers’ promotional tactics have been adept 
at crafting information online12 with, for example, paid 
celebrity endorsements8 and native advertising content.13 It is 
important to consider, however, that patients and caregivers 
are vulnerable populations who may be at life-threatening risk 
or will likely be grasping at straws to survive.1,2,7 Therefore, 
our contribution in academia should be helping policy-
makers to establish comprehensive guidelines so that industry 
can communicate both safely and effectively with consumers. 
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